Match Day 2026: The Next Step Toward Driving Change

Each student at the Icahn School of Medicine at Mount Sinai has their own personal story about what led them to want to become doctors and researchers, but they share a common vision: to improve health care as we currently know it.

For this year’s graduating students, the next step on that journey began with Match Day, when they learned where they will be placed to continue their residency training. On Friday, March 20, 138 students gathered at 583 Park Avenue to receive their placements to training programs in 20 different specialties across the country.

“I hope to see meaningful progress in reducing disparities in access to care,” says Michelle Tran, who is graduating with an MD/PhD and will be continuing her training in internal medicine at the University of California San Diego. “Throughout my training in New York City, I’ve become more aware of the many different types of structural and social barriers that patients face.”

The outgoing class is going into prestigious programs across the nation, including those at Columbia University Irving Medical Center, The Johns Hopkins Hospital, and Massachusetts General Hospital, to name a few.

More than a third of the class—55 students—will advance their training at the Mount Sinai Health System.

Icahn School of Medicine Class of 2026 Top Residency Matches by Specialty

Specialty Number of Matches
Internal Medicine 34
Anesthesiology 16
Psychiatry 11
OB-GYN 9
Click to read more as three graduating students share what drove them to enter the medical profession, insights into their time at the Icahn School of Medicine, and how they envision being able to drive meaningful change in health care as doctors and researchers.

Juan Arroyave Villada

Matched to: Urology at Brigham and Women’s Hospital/Harvard Medical School

What inspired you to enter the field of medicine?

My father is definitely my biggest inspiration in medicine in general. His work as a physician working with HIV patients was always something I admired. Specifically with regard to my interest in urology, my dad’s passing from kidney cancer opened my eyes to the field of urology.

Today I feel inspired to hopefully one day be able to help patients like my father through tough cancer diagnoses and be able to offer the curative solutions that can be offered at early stages.

What were your years like at the Icahn School of Medicine?

I learned that it takes a village to get through the journey, and I’m really grateful to have made it.

M3 (the third year) can be an isolating year, since you are constantly switching rotations and specialties. Dealing with that isolation can be challenging since all of your friends are also on different schedules and even in different places.

I think what helped me navigate this situation the best was being very intentional about keeping relationships going, even if it was just having a simple FaceTime with a friend or studying virtually with someone. I will miss the close relationships that I have with my friends and learning as a medical student.

What change do you hope to achieve as you progress in your medical career?

I hope to improve patient education for vulnerable communities, especially in urology, where there is still a lot of stigma for men to do their preventive screening.

“I am feeling really happy. I’m excited about this next chapter and hopeful that I can continue to grow as a physician. I’m excited to be more hands-on and hope to become a robotic surgeon one day.”

Katharine (Kat) Holmes

Matched to: Physical Medicine and Rehabilitation at Mount Sinai

What inspired you to enter the field of medicine?

My path toward medicine was shaped by my years as a competitive fencer. Even as an athlete, I knew I wanted to eventually serve athletes the way the physicians at Mount Sinai served me, helping future generations reach their potential just as those doctors helped me reach mine.

That aspiration came into sharp focus when I was 15 and suffered my first significant injury—a sprained ankle that sidelined me for a week. That experience was my first real encounter with sports medicine, and I remember thinking: I want to be one of them. From that moment on, the goal never wavered.

What were your years like at the Icahn School of Medicine?

I started at the Icahn School of Medicine three days after I got back from the Tokyo Olympics and did not miss a beat in regard to training or competing. I then qualified for the 2024 Olympic Games during my first two years of medical school. I traveled across the country and around the world during my first two years of medical school, training between two to six hours every day while balancing my studies.

It was the hardest thing I have ever done in my life. But I watched every lecture and never missed a practice or tournament. At the end of the day it really came down to organization. I would wake up every morning and ask myself, “What do I need to do today to pass the next exam and what do I need to do today to get myself ready for my next competition?” I had endless checklists, calendars, and planners. I worked on planes and took exams in between matches at World Cups.

In all honesty, I did not sleep for those two years and, looking back, qualifying for the Olympics while being in medical school seems impossible. I cannot believe that I managed to balance all of it, but somehow, I did! It took every ounce of focus, persistence, and determination that I had. But I guess when you want something badly enough, you are willing to go to any lengths to achieve them.

What change do you hope to achieve as you progress in your medical career?

I see myself contributing to change in health care, particularly at the intersection of sports medicine and research.

The U.S. Olympic Team is composed of some of the most accomplished athletes in the world, supported by world-class Olympic Training Centers, physicians, and sports scientists. Despite these incredible resources, there is still a surprising lack of research leveraging this unique environment.

This is something I’ve been especially motivated to address within fencing. As a smaller and historically under-studied sport, fencing presents a significant opportunity to better understand athlete performance, injury prevention, and training optimization. Through my own work, I’ve aimed to utilize the resources of USA Fencing and the U.S. Olympic & Paralympic Committee to contribute to this growing body of knowledge.

Looking ahead, I hope to expand this model to other similarly under-studied sports. By helping these programs more effectively use the resources available to them, we can improve athlete care, advance performance science, and ultimately support the long-term health and success of athletes across a wider range of disciplines.

“Mount Sinai has always been my dream. It’s USA Fencing’s partner hospital, so from the beginning my goal was to attend Mount Sinai for medical school, match there for residency, and hopefully continue to a Sports Medicine fellowship. I hope to one day serve as a physician for Team USA at the Olympic Games and ultimately stay on as an attending physician at Mount Sinai.”

 

Michelle Tran

Matched to: Internal Medicine on the Physician-Scientist Track Program, followed by a guaranteed Hematology/Oncology fellowship, at University of California San Diego

What inspired you to enter the field of medicine?

I was drawn to medicine through both personal experience and a deep sense of curiosity shaped by my early exposure to science. Growing up in a family where my parents and maternal grandparents were scientists and engineers, I developed a strong interest in understanding how the natural world works.

That curiosity took on a more personal meaning when my grandfather was diagnosed with prostate cancer. Watching him navigate his illness, and witnessing its impact on our family, was a formative experience that drew me toward hematology/oncology.

At the same time, my paternal family’s experience as refugees from the Vietnam War, navigating language barriers and socioeconomic challenges, deepened my awareness of the obstacles many patients face and continues to shape my commitment to caring for diverse and underserved communities.

What were your years like at the Icahn School of Medicine?

One of the most challenging aspects of my time at the Icahn School of Medicine was navigating the uncertainty inherent to research during my PhD years. There were periods when experiments didn’t work as expected or when the data were difficult to interpret, which can be discouraging when progress feels slow.

This was especially true during the early stages of the project that ultimately became my published paper in Cancer Discovery—of which I was first author—where initial findings raised more questions than answers. I overcame these challenges by leaning on mentorship and by shifting my mindset: learning to view unexpected results not as setbacks, but as opportunities to refine the question and think more deeply about biology.

Over time, this experience taught me how to sit with uncertainty, remain persistent, and trust the process. It ultimately made me a more resilient and thoughtful scientist, and it’s a perspective I will carry forward as I continue training as a physician-scientist.

Something I learned, which surprised me, was how important it became for me to stay connected to the communities I care about, even during the most demanding periods of my training. During the spike in xenophobia and anti-Asian hate during the COVID-19 pandemic, I cofounded Soar Over Hate, which evolved into a 501(c)3 nonprofit focused on combating anti-Asian hate and expanding access to safety resources for vulnerable communities.

Balancing this work alongside clinical rotations and PhD research, there were many moments where things felt uncertain or overwhelming. Staying engaged in this work grounded me and gave my training a deeper sense of purpose. That perspective continues to shape how I approach both patient care and scientific discovery.

What change do you hope to achieve as you progress in your medical career?

As I continue my training, I hope to contribute to change in health care through both clinical care and research. As a future physician-scientist in hematology/oncology, I’m particularly interested in improving how we understand and treat cancer by bridging mechanistic insights with patient care. I hope to help advance more precise and effective therapies, by addressing why patients respond differently to treatment.

I’m motivated by the opportunity to better understand why some patients respond to therapy while others do not, and to translate those insights into more effective and personalized treatments that can meaningfully improve patients’ lives.

More broadly, I hope to see meaningful progress in reducing disparities in access to care. Throughout my training in New York City, I’ve become more aware of the many different types of structural and social barriers that patients face. I hope to be part of efforts that make care more equitable, accessible, and responsive to the needs of diverse communities.

“I’m immensely grateful and excited to have matched at UC San Diego. It’s a program that strongly aligns with both my clinical and research interests, and I’m especially looking forward to returning to Southern California to be closer to my family. At the same time, it’s bittersweet to leave the Mount Sinai community, which has been such an important part of my growth over the past eight years of my MD/PhD training.”

Advancing Toward Medicine: How Mount Sinai’s MSBS Program Is Shaping a Path to a Physician-Scientist Career

“Mount Sinai offered the opportunity to grow as both a scientist and a future physician while being part of a community deeply committed to patient care,” says Alexander Forrest, a first-year student in the Master of Science in Biomedical Science program. “And as a New Yorker at heart, it felt like the right place for me both professionally and personally.”

Alexander Forrest is a first-year student in Track 1 of the Master of Science in Biomedical Science program at the Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai with a concentration in Immunology.

In this Q&A, he discusses how the mentorship, community engagement, and translational research at Mount Sinai are building the foundation for his future career as a physician-scientist.

“Mount Sinai offered the opportunity to grow as both a scientist and a future physician while being part of a community deeply committed to patient care,” he says. “And as a New Yorker at heart, it felt like the right place for me both professionally and personally.”

What is your academic and career background?

I graduated from Hunter College in 2023, where I majored in biochemistry. During my time there, my professors emphasized the importance of research in deepening our understanding of biological systems. This led me to participate in several summer research programs, where I developed both technical skills and a strong foundation in asking and answering scientific questions. I also served as a neuroscience instructor for high school seniors. I later returned to one of my summer programs as a research mentor, which deepened my interest in both science and education. After graduating, I worked as a research technician at the Albert Einstein College of Medicine, studying metabolic pathways in thyroid cancer.

What first attracted you to this field?

I grew up primarily in the Caribbean, on the island of Antigua, where research and laboratory science were not always widely visible career paths. I’ve always been driven by curiosity and a desire to understand how things work. Additionally, seeing family members navigate illness motivated my interest in contributing to the development of new treatments and cures. Over time, through my experiences in research, I realized that this was something I could see myself pursuing long-term.

Why did you choose to study at Mount Sinai?

During my gap years, I was looking for an environment where I could take greater ownership of my work while also gaining more exposure to clinical care and community engagement. At the same time, I wanted to be in a place pushing forward impactful, translational research. Mount Sinai stood out as a place where all these elements intersect. It offered the opportunity to grow as both a scientist and a future physician while being part of a community deeply committed to patient care. And as a New Yorker at heart, it felt like the right place for me both professionally and personally.

Who are your mentors, and what is the focus of your research?

At Mount Sinai, I work under the mentorship of Brian Brown, PhD, alongside Alessia Baccarini, PhD, and Xiao Han, PhD. The lab environment is highly collaborative and driven by a shared commitment to tackling complex biological questions. Our research focuses on understanding how the immune system influences the proliferation and persistence of ovarian cancer, with the goal of developing therapeutic strategies to overcome immune evasion.

What has been your greatest accomplishment in the program so far?

One of my biggest accomplishments has been successfully transitioning back into an academic environment after time away from school. Beyond that, I serve as co-chair of Access to Care Team Resources within the East Harlem Health Outreach Partnership, where I help address barriers to care for patients, including transportation and food access. This work has been especially meaningful, as it allows me to directly support patients navigating the health care system. I also had the opportunity to speak with high school students about careers in science earlier this year, which was a full-circle moment given my own path.

How have the resources at Mount Sinai contributed to your success in the program?

Mount Sinai provides an incredibly supportive environment, both academically and personally. The administration has been helpful in navigating the program, and my lab has been a major source of mentorship and growth. Equally important is the sense of community among students and trainees. There’s a shared drive to succeed, but also a genuine willingness to support one another. That balance has made a big difference in my experience here.

What are your plans after you complete your MSBS?

After completing the program, I plan to apply to medical school, with a particular interest in MD/PhD programs. I hope to build on the skills I’ve developed at Mount Sinai to become a physician-scientist who can bridge patient care and research, contributing to both improved treatments and a deeper

Addressing the Cognition Concerns of Multiple Sclerosis Patients

Sarah Levy, PhD

Multiple sclerosis (MS) patients often worry that the disease will diminish their ability to think and remember, along with their motor skills. Sarah Levy, PhD, Assistant Professor of Neurology at the Icahn School of Medicine at Mount Sinai, is working to address these concerns, studying the impact of MS on the brain and cognition and uncovering new possibilities for early interventions.

Dr. Levy arrived at Mount Sinai’s Corinne Goldsmith Dickinson Center for Multiple Sclerosis in 2020 with a PhD in clinical psychology and a passion for neuropsychology and neuroscience. She didn’t have extensive experience working with MS patients. But she knew that at the MS Center, she would be able to delve into an area that can be extremely concerning for patients when they receive an MS diagnosis: The potential effects of the condition on thinking and memory.

She was drawn to do a post-doctorate fellowship at Mount Sinai with James Sumowski, PhD, who researches modifiable risk and protective factors linked to cognitive decline.

“My prior research experience largely involved neuroimaging, which plays a central role in MS diagnosis and care,” says Dr. Levy, who is also Associate Director of the MS Cognitive Clinic. “Coming here allowed me to connect that work more directly to questions about cognition and brain–behavior relationships.”

As a result, Dr. Levy stayed on as faculty after her postdoc ended in 2022. Her current research focuses on several crucial areas, including how MS affects cognition; the possible impact of subtle neuroanatomical changes in the brain caused by the disease; and how MS affects cognition as patients age.

MS may affect patients’ thinking, but not in the ways researchers once thought

Besides affecting sensorimotor skills such as balance and coordination, clinicians and researchers have long known that MS can also affect a patient’s thinking and memory. But just as the latest disease-modifying therapies (DMTs) have helped keep severe motor symptoms at bay, these medications may also be changing the outlook for patients when it comes to their cognitive abilities.

Statistics show up to 70 percent of people with MS experience cognitive changes, particularly memory problems and slower information processing. But that outlook has changed with medications that work to quiet the disease’s signature lesions that can appear in the brain’s white matter, according to Dr. Levy.

“These lesions have been associated with cognitive dysfunction, but with our current DMTs, we can stop the formation of new lesions much better than in the past,” Dr. Levy says. “As a result, some cognitive issues, particularly processing speed, are less pronounced than before.”

For example, in a study recently published in the journal Brain, Dr. Sumowski, Dr. Levy and others at the MS Center found that patients with relapsing-remitting MS had normal processing speed, and slowed processing speed is now less of an issue for patients with progressive MS than previously.

That doesn’t mean MS has no effect on cognition. “Since our DMTs help reduce inflammation and protect against cognitive changes, cognition in MS patients now looks different and better,” says Dr. Levy.

She describes the cognitive issues as more subtle, and sometimes easier for patients to work around, but still frustrating. “We’re talking about things like word-finding difficulties, which are the number one cognitive complaint from our patients.”

The other concerns she hears from her MS patients: Losing one’s train of thought in a conversation; forgetting why they came into a room; and the dreaded “brain fog.”

“Many people with MS figure out how to navigate these challenges on their own. But we are working on how we can help with therapies such as cognitive remediation, which addresses these challenges by teaching practical strategies that patients can use every day,” she says.

MS, dementia and aging

Having trouble finding words is also something that happens with normal aging, which can make it difficult to determine whether a patient’s cognitive changes are due to MS or simply getting older. “It can be hard to tell the difference,” says Dr. Levy, who is studying what cognitive aging looks like in MS.

To better understand these distinctions, her current research is expanding to examine how age-related changes in MS compare with changes seen in other conditions, such as Alzheimer’s disease. She is recruiting participants for a study that uses PET scans and blood biomarkers to help make this distinction.

“Those with Alzheimer’s disease have what’s known as a buildup of beta-amyloid proteins in the brain. “In this study, we’ll look for these proteins in patients and combine that with comprehensive neuropsychological testing to see how patients with MS who don’t have these proteins differ from older adults without MS who do.” Early research suggests that people with MS may have lower rates of beta-amyloid in the brain.

“Anecdotally, we don’t often see people with MS with the kind of dense forgetting that occurs with Alzheimer’s disease,” she says. “I have patients with MS in their 70s and 80s who are fully oriented to things like date, time, and where they are—that’s very different from what we see in Alzheimer’s. And while it’s too early to know for sure, it’s an interesting question whether people with MS might have some protection from the disease.”

White matter vs. gray matter in the brain

Another way thinking about MS is changing: For decades, MS was thought of as an inflammatory condition that primarily affected the white matter in the brain. Now, researchers are learning that the gray matter may also be affected.

“In my research, I’m interested in the subtle neuroanatomical changes that may occur in the brain’s gray matter early on in MS, as well as the subtle cognitive changes that might bring,” says Dr. Levy.

Using neuroimaging in collaboration with Erin Beck, MD, PhD, Dr. Levy has found that early on, in some patients, there may be a very subtle loss in the thickness of the gray matter in the brain, known as cortical thickness.

These findings, she stresses, shouldn’t be cause for alarm. “I don’t want to worry patients,” Dr. Levy says. “We are talking about very subtle findings, micro changes, so small they are typically not even mentioned in a radiological report.”

While researchers are still learning about what these changes might mean, and how they might be related to possible cognitive and motor function, the research nevertheless holds promise for improving patients’ quality of life.

“These changes tend to occur very early on in the disease, which means we could have an opportunity to try immediate interventions, such as teaching patients strategies to compensate for possible cognitive changes, or even dietary changes, to help protect the brain,” she says.

Promise in protecting and helping the brain in people with MS

With advances in neuroimaging, clinicians are now able to detect MS at earlier, milder stages, and better understand what the disease looks like early on. That means that, with earlier intervention using DMTs alongside lifestyle modifications in diet, exercise, and sleep, clinicians can better protect patients’ cognitive health.

For MS patients experiencing cognitive symptoms—and even those who are not—Mount Sinai offers a comprehensive neuropsychological assessment clinic to help patients and their doctors get a sense of where they are.

“For every patient who comes through the MS Center, we can provide a baseline neuropsychological exam that looks at memory, attention, language, sensorimotor skills, and executive functioning,” says Dr. Levy. Then we can use this information for comparison over the years, if patients continue with regular testing.

“Just like we use MRIs to track lesions, we can track a patient’s cognitive function over time,” says Dr. Levy.

Mount Sinai neuropsychologists can also look for changes in mood, depression, anxiety, and sleep. “We can relay this information to our neurologists and point patients to interventions that might be helpful,” says Dr. Levy.

Mount Sinai also offers MS patients access to The C. Olsten Wellness Program, directed by Ilana Katz Sand, MD, and staffed with a nurse practitioner, physical therapist, a dietician, and social workers.

But patients are the true experts in what they are experiencing, whether changes in word-finding or walking.

“By listening carefully, we can keep adapting our clinical evaluations to be more sensitive to the issues patients are reporting,” says Dr. Levy. “It’s truly our patients who have allowed us to learn and understand what is happening in the brain, helping us advance the field in a meaningful way—and also shaping the way we care for them.”

If you are interested in participating in Dr. Levy’s forthcoming PET imaging study on cognitive aging and Alzheimer’s disease in MS, you can reach out to her directly at 347-503-5471 or email her at sarah.levy@mssm.edu.

By Paula Derrow

He Was Cured of Cancer at Mount Sinai Two Decades Ago. Now This Actor’s Cancer Experience Informs His Latest Stage Role

Actor Jay Russell, Courtesy of Paper Mill Playhouse

Actors often call on their own experiences when developing a character for the stage. But few have the depth of understanding that 21-year head and neck cancer survivor Jay Russell brings to the role of Caesar Rodney in the musical 1776, playing at Paper Mill Playhouse in Millburn, New Jersey, from Wednesday, April 1, to Saturday, May 2.

The Tony Award-winning show portrays the events leading up to the signing of the Declaration of Independence. Mr. Rodney, a delegate to the Continental Congress, struggled with his own cancer that affected his face throughout this period and eventually died of the disease. In what was arguably his most influential act, he cast a decisive vote for independence.

The actor’s cancer journey began in 2004, when he discovered a lump in his neck. Doctors at what was then called Beth Israel Medical Center took a biopsy, which showed squamous cell carcinoma, a cancer that can arise in the head and neck region. It had started in his right tonsil, then spread to the lymph nodes in his neck. Treatment included surgery, chemotherapy, and radiation. Due to the location of the tumor, Mr. Russell used a feeding tube, which led to a 40-pound weight loss.

“I’m an actor. I take direction well, so I did everything they said to do,” he says. He was back at work about 11 months after the start of treatment. “They took excellent care of me.”

The treatment was successful, and more than two decades later he remains cancer-free. (And in that time, the hospital became Mount Sinai Beth Israel, which closed in 2025.)

“There’s some asymmetry to my face and I sometimes have difficulty swallowing, but my speaking and singing voice came through unscathed,” says Mr. Russell, who has since performed on- and off-Broadway, on national tours and regional theatres, and on film and television.

We know less about Caesar Rodney’s medical story back in the 18th century. There was no effective treatment for his cancer at that time, though reports indicate that a doctor operated on his nose, leaving him disfigured. According to reports, he rarely went out in public without a green scarf covering part of his face.

But he didn’t let his illness stand in his way. Mr. Rodney served as an officer in the Delaware militia, a delegate to the Continental Congress, and governor of Delaware. His history-making moment came when the Continental Congress was voting on whether to declare independence from Britain. At that point, Mr. Rodney was in Dover, Delaware. The other two Delaware delegates were at an impasse in Philadelphia; one delegate was against declaring independence, the other for it. They needed someone to break the tie and get a “yes” vote from Delaware.

Mr. Russell (back row, fourth from right) with the cast of the musical 1776. Photo credited to Rebecca J Michelson.

In the film version of 1776, Mr. Rodney was back home recuperating from his disease; the film portrays him as a frail, elderly man. But the historical record suggests that he was in his late 40s, pragmatic, and back in Dover dealing with the Delaware militia. So, a bit of a different story is told in 1776.

“I imagine our director wanted to cast someone who had strength and resilience,” says Mr. Russell.

In real life and in the show, as soon as he received the message that he was needed urgently, Mr. Rodney jumped on a horse and rode 18 hours through a torrential storm to Philadelphia. He arrived muddy, exhausted, and eager to cast his vote to cut ties with Britain.

Mr. Russell says his personal experience overcoming adversity helps him understand what it was like for the historical figure.

“No matter how strong, resilient, and admirable Rodney was, he was in great pain and discomfort having this untreatable cancer on his face,” he says. “I will certainly use my own memories of the pain, the treatment, and the experience that I had in portraying Rodney.”

That’s not the only lesson Mr. Russell brings to his portrayal of the historical figure.

“Rodney’s diagnosis led him to understand how precious time was and how he had to use every moment,” says Mr. Russell. The politician used that moment to help bring independence to the 13 colonies. The actor brings it to share that important story on stage.

Besides being the 250th anniversary of 1776, Mr. Russell believes the musical’s revival is extremely timely. “This show celebrates the core of what made us a country, and how differing viewpoints can unite and come together for the common good,” he says.

 

She Didn’t Think Much of the Pain in Her Jaw, But She Was Having a Heart Attack: Doctors Say Don’t Ignore Your Symptoms

When Jessica Rodriguez, 55,  experienced sudden, severe jaw pain one evening, she assumed it was related to recent dental work. But as the pain worsened overnight, she trusted her instincts and sought emergency care—a decision that saved her life.

At Mount Sinai Queens, Ms. Rodriguez was treated by Jonathan L. Murphy, MD, an interventional cardiologist, who quickly identified that she was having a severe heart attack, despite her initial symptoms being subtle. Additional testing revealed a 100 percent blockage in her right coronary artery, and Dr. Murphy immediately performed a life-saving stent procedure to restore blood flow to her heart.

Jonathan L. Murphy, MD. Click here to make an appointment.

“Heart attacks don’t always present as chest pain, especially in women,” says Dr. Murphy. “Symptoms like jaw pain, back pain, fatigue, or shortness of breath can be warning signs and should never be ignored.”

Thanks to rapid diagnosis and treatment, Ms. Rodriguez recovered quickly and returned home within a day. She has since made lifestyle changes to support her heart health, including increasing physical activity, improving her diet, and working to quit smoking, while also learning about her family history of heart disease.

Dr. Murphy emphasizes the importance of self-monitoring and self-advocacy. “If something doesn’t feel right, listen to your body and seek care,” he says. “Acting early can save your life.”

Ms. Rodriguez, a Queens resident, now shares her story to encourage others—especially women—to take symptoms seriously.

“I almost talked myself out of getting help,” she says. “Trusting myself made all the difference.”

How Much Do You Know About Colorectal Cancer? Take the Quiz

Colorectal cancer is now the leading cause of cancer deaths in the United States for both men and women under the age of 50. There are many misconceptions about the disease, and knowing the facts can help you fight it. Can you separate myth from fact? Take the quiz below, then click “Done” to see your score and correct answers.

This quiz was developed with Pascale White, MD, MBA, MS, FACG, Director of Health Equity in Action for Liver and Digestive Diseases and Associate Professor of Medicine (Gastroenterology and Liver Disease) at the Icahn School of Medicine at Mount Sinai.

 

Create your own user feedback survey